A single Type B meeting has moved AMT-130 from a Phase I/II gene therapy experiment into active BLA territory, with uniQure targeting a Q3 2026 submission built almost entirely on 36-month data from fewer than 40 treated patients. That is a remarkably thin clinical foundation by conventional standards, but the numbers behind it are hard to dismiss: high-dose AMT-130 demonstrated a statistically significant 75% slowing of disease progression on the composite Unified Huntington’s Disease Rating Scale at the three-year mark, a result that cleared the prespecified primary endpoint in a disease where available therapies manage symptoms rather than biology. Tetrabenazine and deutetrabenazine address chorea; nothing currently approved touches the underlying neurodegenerative trajectory in Huntington’s patients.
The regulatory architecture here is worth unpacking. FDA accepted that propensity score-matched external controls drawn from the Enroll-HD natural history registry, now encompassing more than 30,000 participants, can stand in as the primary comparator arm for the BLA. That is an unconventional but increasingly defensible approach for rare neurological diseases where randomized sham-controlled trials are ethically contested and operationally brutal. What FDA also signaled, though, is that it wants the confirmatory study design locked before submission, and it is already nudging uniQure away from a sham control toward a concurrent standard-of-care comparator arm. That shift matters enormously for patient recruitment, blinding logistics, and the eventual label claim uniQure can make if the confirmatory trial reads out.
AMT-130 carries Breakthrough Therapy designation, Fast Track designation, and the first RMAT designation granted for Huntington’s disease, a combination that gives uniQure rolling review eligibility and intensive FDA collaboration rights. Those designations exist precisely for moments like this, where a single-administration gene therapy delivered by MRI-guided stereotactic neurosurgery into the striatum is being evaluated on a compressed evidence base under accelerated approval. The therapy’s one-time delivery profile also sidesteps the chronic dosing and adherence complexities that complicate most neurological disease management, but it pushes manufacturing consistency and surgical standardization to the foreground of any commercial launch conversation.
The decisive variable to track now is not the BLA submission itself but whether uniQure and FDA reach written alignment on the confirmatory study design before the Q3 2026 filing date. Accelerated approval lives or dies on the post-market commitment, and any ambiguity in the confirmatory protocol at submission will surface as a condition FDA can use to stall or restrict the label. Watch the final meeting minutes, due within 30 days, for whether the standard-of-care control arm is described as agreed or still under discussion.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
